Phenotyping of Evi1, Evi11/Cb2, and Evi12 transformed leukemias isolated from a novel panel of cas-Br-M murine leukemia virus-infected mice.
Cas-Br-M murine leukemia virus (MuLV) is a slow-transforming retrovirus that potently induces leukemias in mice and therefore is well suited for retroviral insertional mutagenesis. We used Cas-Br-M MuLV in NIH/Swiss mice to establish a new panel of mainly myeloid leukemias. All tumors found in leukemic animals were classified by gross pathology, morphology, and immunophenotype, as well as the incidence of known common virus integration sites (VISs) in MuLV-induced myeloid malignancies (i.e., Evi1, Evi11/Cb2, Evi12, Fli1, and c-Myb). Interestingly, male mice were more susceptible than females to the induction of leukemia by Cas-Br-M MuLV. Seventy-four of the Cas-Br-M MuLV-inoculated mice developed a severe splenomegaly, sometimes in association with a thymoma. Although most of the immunophenotyped Cas-Br-M MuLV tumors were of myeloid origin (58%), numerous T-cell leukemias (21%) and mixed myeloid/T-cell leukemias (21%) were found. The myeloid leukemias and myeloid compartment of the mixed leukemias were further characterized by immunophenotyping with stem cell-, myeloid-, and erythroid-specific antibodies. The known Cas-Br-M MuLV common VISs (Evi1, Evi11/Cb2, and Evi12) were demonstrated in 19%, 12%, and 20% of the cases, respectively, whereas no Fli1 and c-Myb rearrangements were found. Integrations into Evi1 were restricted to myeloid leukemias, whereas those in Evi11/Cb2 and Evi12 were identified in myeloid as well as T-lymphoid leukemias. This panel of well characterized Cas-Br-M MuLV-induced hematopoietic tumors may be useful for the isolation and characterization of new proto-oncogenes involved in myeloid or T-cell leukemias.
Joosten
M
M
Institute of Hematology, Erasmus University Rotterdam, Rotterdam, 3000 DR, The Netherlands.
Valk
P J
PJ
Vankan
Y
Y
de Both
N
N
Löwenberg
B
B
Delwel
R
R
D016475:3T3 Cells; D000818:Animals; D002472:Cell Transformation, Viral; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D009052:Leukemia Virus, Murine / Q000235:genetics*; D007942:Leukemia, Experimental / Q000235:genetics / Q000473:pathology / Q000821:virology*; D000074008:MDS1 and EVI1 Complex Locus Protein; D008297:Male; D051379:Mice; D010641:Phenotype; D011518:Proto-Oncogene Proteins / Q000302:isolation & purification / Q000502:physiology; D011519:Proto-Oncogenes; D012192:Retroviridae Infections / Q000235:genetics / Q000473:pathology / Q000821:virology*; D014157:Transcription Factors; D014412:Tumor Virus Infections / Q000235:genetics / Q000473:pathology / Q000821:virology*; D016662:Virus Integration / Q000235:genetics*
D004268:DNA-Binding Proteins; D000074008:MDS1 and EVI1 Complex Locus Protein; C499305:Mecom protein, mouse; D011518:Proto-Oncogene Proteins; D014157:Transcription Factors